Edgewise Therapeutics, Inc.(EWTX)Earnings, Financials & Key RatiosEdgewise Therapeutics, Inc. (EWTX) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's persistent free cash flow deficit of $42.8 million in 2026Q1 and the rapid depletion of cash reserves to $33.2 million present substantial execution risks for long-term investors.
Edgewise Therapeutics, Inc. (EWTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Edgewise Therapeutics, Inc. (EWTX) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.46vs $0.50+8.0% | — |
| Q1 2026 | Feb 26, 2026 | $0.47vs $0.43-9.3% | — |
| Q4 2025 | Nov 6, 2025 | $0.39vs $0.40+2.5% | — |
| Q3 2025 | Aug 7, 2025 | $0.34vs $0.42+19.0% | — |
Recent stock market news and headlines for Edgewise Therapeutics, Inc. (EWTX)
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript
Edgewise Therapeutics Inc. (NASDAQ:EWTX) on Tuesday released topline results from the 12-week Part D cohort of its Phase 2 CIRRUS-HCM trial.
Edgewise Therapeutics shares fell nearly 10% on Tuesday after the efficacy of its experimental heart-disease drug in a mid-stage study fell short of investor expectations.
– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers, symptoms and functional status across obstructive and nonobstructive HCM – – EDG-7500 administration continued to be generally well tolerated – – Company to host webcast today at 8:30 a.m. Eastern Time – BOULDER, Colo.
Key metrics vs top competitors for Edgewise Therapeutics, Inc. (EWTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $39.15 | $4.21B | -24.02 | — | — | -34.19% | — | |
| $25.20 | $4.31B | 11.00 | 11.87% | 34.3% | 35.65% | — | |
| $114.20 | $9.32B | -30.95 | -16.72% | -612.17% | -25.02% | — | |
| $13.29 | $1.28B | -4.31 | — | — | -151.02% | — | |
| $38.14 | $7.83B | -13.77 | — | — | -68.16% | — | |
| $25.84 | $3.23B | -198.77 | 91.34% | -0.57% | -1.41% | — |
Edgewise Therapeutics, Inc. (EWTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Edgewise Therapeutics, Inc. (EWTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 7, 2026·SEC
Feb 26, 2026·SEC
Nov 20, 2025·SEC
Get notified when EWTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Edgewise Therapeutics, Inc. (EWTX) stock FAQ — growth, dividends, profitability & financials explained
Edgewise Therapeutics, Inc. (EWTX) reported a net loss of $176.0M for fiscal year 2025.
Edgewise Therapeutics, Inc. (EWTX) has a return on equity (ROE) of -34.2%. Negative ROE indicates the company is unprofitable.
Edgewise Therapeutics, Inc. (EWTX) had negative free cash flow of $148.7M in fiscal year 2025, likely due to heavy capital investments.
